Targeted therapy kills lymphoma cells, leaves healthy cells alone

Share this content:
Researchers from the Ontario Cancer Institute (OCI) have discovered a way to destroy a cancer-causing protein using a chemical compound.

In a study using three-dimensional crystallography and computer-aided drug design, co-principal investigator Gilbert Privé, an OCI senior scientist, and colleagues filtered more than 1 million potential compounds down to one compound that proved not only to be successful at killing lymphoma cells but also was nontoxic.

Results showed that a cancer-causing protein, BCL6, was blocked by researchers using the chemical compound they initially identified. “If you picture cell proteins as a circuit board, we have found a way to short-circuit a defective connection without destroying the entire board,” explained Dr. Privé.

“We have identified a new avenue for drug development,” said Dr. Privé. “It is exciting because until now, the prevailing wisdom has been that cancer proteins such as BCL6 would not respond in this way to chemical manipulation. We have proven otherwise.”

The findings were published in Cancer Cell (2010 Apr 13;17(4):400-11).

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs